Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN), Twist Bioscience (TW...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) wi...

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX)

Biogen Inc. (($BIIB)) has held its Q1 earnings call. Read on for the main highlights of the call. Biogen’s latest earnings call struck a cautiously...

Biogen Earnings Call Signals Confident, Investment-Heavy Transition

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Keros Therapeutics (KROS), Cormedix (CRMD) and Bio...

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Cormedix (CRMD) and Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB), RegenXBio (RGNX) and Dexcom (DXCM) wi...

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), RegenXBio (RGNX)

Wells Fargo analyst Mohit Bansal assigned a Buy rating to Biogen yesterday and set a price target of $250.00. The company’s shares closed yesterday...

Wells Fargo Issues a Buy Rating on Biogen (BIIB)

In a report released today, Emily Field from Barclays maintained a Hold rating on Biogen, with a price target of $185.00. According to TipRanks, Fi...

Biogen (BIIB) Gets a Hold from Barclays

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is running a Phase 1 study called “A Phase 1, Randomize...

Biogen’s SKYCLARYS Formulation Study: What a New Liquid Tablet Could Mean for BIIB Investors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (...

Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (IART) and Biogen (BIIB)

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen, with a price target of $215.00. According to TipRanks, Nad...

TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Definium Therapeutics (DFTX) with ...

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX)

In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen, with a price target of $245.00. Kulkarni cove...

Canaccord Genuity Sticks to Its Buy Rating for Biogen (BIIB)

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen, with a price target of $196.00. According to TipRan...

BMO Capital Reaffirms Their Hold Rating on Biogen (BIIB)

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen, with a price target of $206.00. According to TipR...

Morgan Stanley Remains a Hold on Biogen (BIIB)

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen, with a price target of $222.00. The company’s sh...

RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cullinan Management (CGEM), Biogen (BIIB) and Cross Country Healt...

Current Quarter	$3.36	Next Quarter	$3.9
Current Year	$14.18	Next Year	$16.56
QoQ Growth	+16.1%	YoY Growth	+16.8%
3Y EPS CAGR	-25.0%	Target Price	$218.97
Consensus	Buy	Upside	+13.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIIB	$193.08	-0.35%	930.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIIB	$193.08	-0.4%	930.11K
3
4
5
6

BIIB

BIIB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Biogen Inc. Data in Excel

Get Biogen Inc. Data in Excel